Tenofovir Alafenamide Hemifumarate TAF CAS 1392275-56-7 API Factory Anti-HIV High Quality

Short Description:

Name: Tenofovir Alafenamide Hemifumarate (TAF)

CAS: 1392275-56-7

White to Almost White Crystals or Crystalline Powder

Assay: 98.0%~102.0%

A prodrug for Tenofovir, used in combination therapy for the treatment of HIV-1 Infection

High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Commercial Supply Tenofovir Related Intermediates:
Tenofovir CAS: 147127-20-6
Tenofovir Disoproxil Fumarate CAS 202138-50-9
Tenofovir Alafenamide Hemifumarate CAS 1392275-56-7
Chloromethyl Isopropyl Carbonate CAS 35180-01-9
Diethyl (p-Toluenesulfonyloxymethyl)phosphonate CAS 31618-90-3
(R)-(+)-Propylene Carbonate CAS 16606-55-6
(R)-9-(2-Hydroxypropyl)adenine CAS 14047-28-0
Diethyl (Hydroxymethyl)phosphonate CAS 3084-40-0
Adenine CAS 73-24-5

Chemical Properties:

Chemical Name	Tenofovir Alafenamide Hemifumarate
Synonyms	TAF; GS-7340 Hemifumarate
CAS Number	1392275-56-7
CAT Number	RF-API91
Stock Status	In Stock, Production Scale Up to Hundreds of Kilograms
Molecular Formula	C25H33N6O9P
Molecular Weight	592.55
Storage Temperature	Sealed in Dry, Room Temperature
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White to Almost White Crystals or Crystalline Powder
Solubility	Soluble in Dimethylformamide, and Methanol; Sparingly Soluble in Water and THF; Slightly Soluble in Acetonitrile and Insoluble in Dichloromethane and Toluene
Identification A	The IR absorption spectra should be consistent with the reference
Identification B	The retention time of the major peak of the sample solution in the content determination chromatogram conforms to that of the reference solution
Identification C	The Fumaric Acid retention time of the major peak in the content determination chromatogram conforms to the peak of the reference
Water Content (by K.F)	≤1.0%
Clarity of Solution	Basically no visible particles in 2% (w/v) of the Methanol Solution clarification
Residual Solvent
Acetonitrile	≤410ppm
Ethanol	≤5000ppm
Dichloromethane	≤600ppm
Toluene	≤890ppm
Residue on Ignition	≤0.10%
Heavy Metals	≤20ppm
Related Substances
PMPA	≤1.0%
PMPA Anhydride	≤0.75%
Single Phenyl PMPA	≤1.0%
Any Unspecified Impurity	≤0.15%
Total Impurities	≤2.0%
Isomer	≤1.0%
Content of Fumaric Acid	9.0%~13.0% (on the anhydrous basis )
Microbial Limits
Total Aerobic Microbial Count	≤1000CFU/g
Total Yeasts and Molds Count	≤100CFU/g
Escherichia Coli	Absent
Assay	98.0%~102.0% (on the anhydrous and solvent-free basis )
Test Standard	Enterprise Standard

Package & Storage:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Advantages:

FAQ:

Application:

Tenofovir Alafenamide Hemifumarate (TAF, GS-7340 hemifumarate), CAS 1392275-56-7, is a nucleotide reverse transcriptase inhibitor (NRTIs) and a novel prodrug of Tenofovir (TFV). By blocking reverse transcriptase, TAF prevent HIV from multiplying and can reduce the amount of HIV in the body. Tenofovir alafenamide is a prodrug, which means that it is an inactive drug. In the body, tenofovir alafenamide is converted to Tenofovir diphosphate (TFV-DP). Tenofovir Alafenamide Fumarate was approved in November 2015 for treatment of HIV-1.